Press Archive
- Charles Francis: Weakening eye surgery laws places WV patients in jeopardy
- Mark D. Mayle, MD - 2022 Secretariat Award Recipients
- Dr. Larry Schwab recognized with 2020 International Blindness Prevention Award
- Wow Moment with Joseph A. LoCasio | Bio-Tissue | #WowWednesdays
- WVU Today | Moore, Oppe named recipients of Heebink award for Distinguished Service
- Cornea Transplant Restores Young Boy’s Sight After Fishing Accident
- Keep your eyes healthy and safe in the workplace
- Glaucoma Awareness Month
- Ophthalmologists Say 90 Percent of Work-Related Eye Injuries Can be Avoided by Wearing Eye Protection
- Five Tips to Avoid Toy-Related Eye Injuries
- Details
To determine the prevalence of age-related cataract and its ancestral and socioeconomic risk factors in a multi-ethnic Asian population.
Read more: Ancestry, Socioeconomic Status, and Age-Related Cataract in Asians
- Details
To investigate the longitudinal alterations of subbasal corneal nerves in patients with infectious keratitis (IK) during the acute phase, cessation of treatment, and the recovery phase by in vivo confocal microscopy (IVCM).
Read more: Degeneration and Regeneration of Subbasal Corneal Nerves after Infectious Keratitis
- Details
To describe the prevalence of choroidal nevus in the US population and identify possible associated factors.
Read more: Choroidal Nevus in the United States Adult Population
- Details
Throughout history, much of medical science has been based largely on observation. In recent decades, evidence-based medicine, which is defined as “the conscientious, explicit, and judicious use of current best evidence in making decisions about the care of individual patients,”1 has shifted the ideal for how we practice medicine. Whereas observational research has proven to be useful in the past, it is now accepted that the opportunity for bias and confounding decreases with certain methodologic research designs, offering greater internal and external validity than mere observation.
- Details
Lifitegrast is an integrin antagonist that decreases T-cell–mediated inflammation associated with dry eye disease (DED). We report the results of OPUS-2, a phase III study evaluating the efficacy and safety of lifitegrast compared with placebo for the treatment of DED.
Read more: Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease
- Details
To evaluate the 2-year outcomes of uveitic macular edema.